New hope drug enters human testing for Tough-to-Treat blood cancers
Disease control
Recruiting now
This early-stage trial is testing a new drug called NB02 (posseltinib) in patients with non-Hodgkin's lymphoma that has returned or stopped responding to standard treatments. The main goal is to find the safest dose and understand how the drug behaves in the body. Researchers wil…
Phase: PHASE1 • Sponsor: NOBO Medicine • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC